TREE NEWS reports: Novartis shares fell 10% in European trading after the company disclosed its third clinical trial setback within a week. The latest failure adds to investor concerns over the pharma giant’s pipeline. No further details were provided in the initial report.
Novartis shares drop 10% after third clinical trial setback in a week
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
7m ago
BYD Sets 2027 Overseas Sales Target Above 2.5 Million Units
25m ago
Universal Scientific Industrial Aug Revenue Up 17.12% YoY
27m ago
Asia debt issuance surges as banks lead borrowing spree
30m ago
Shanghai Exchange official: long-term funds accelerating into China’s hard tech
59m ago
China A-share turnover hits 1.96 trillion yuan on Sep 8
1h ago
China Stocks Mixed; Ag Shares Surge, ChiNext Down 1.15%